Published in J Pharmacol Exp Ther on January 01, 1971
Effects of nerve stimulation and of administration of noradrenaline or potassium chloride upon the release of prostaglandins, I2, E2, and F2 alpha from te perfused mesenteric arterial bed of the rabbit. Br J Pharmacol (1981) 0.91
Effect of prostaglandins E 1 , E 2 and A 2 on vascular resistance and responses to noradrenaline, nerve stimulation and angiotensin in the dog hindlimb. Br J Pharmacol (1972) 0.90
Modification of responses to sympathetic nerve stimulation by the renin-angiotensin system in rats. Br J Pharmacol (1974) 0.86
Salivation induced by prostaglandin F 2 and modification of the response by atropine and physostigmine. Br J Pharmacol (1972) 0.80
The potentiation of exogenous noradrenaline by prostaglandins F 2alpha C2 and D2 on the canine saphenous vein [proceedings]. Br J Pharmacol (1977) 0.79
Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther (1981) 6.71
The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol (1985) 3.29
Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat. Am J Physiol (1981) 3.18
Relationship between cyclic guanosine 3':5'-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J Pharmacol Exp Ther (1981) 3.14
Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res (1979) 3.11
A new class of angiotensin-converting enzyme inhibitors. Nature (1980) 3.03
Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther (1986) 2.64
Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta (1982) 2.00
Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. J Pharmacol Exp Ther (1984) 1.85
Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can J Physiol Pharmacol (1981) 1.74
Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun (2001) 1.74
Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol (1983) 1.68
In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation (2000) 1.55
Prostaglandins as modulators of the autonomic nervous system. Fed Proc (1974) 1.54
Influence of acetylcholine on contractile force and cyclic nucleotide levels in the isolated perfused rat heart. J Pharmacol Exp Ther (1973) 1.48
Identification and specific blockade of two receptors for histamine in the cardiovascular system. J Pharmacol Exp Ther (1976) 1.47
Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther (1981) 1.44
Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens (1995) 1.40
Enhancement of renal blood flow by furosemide. J Pharmacol Exp Ther (1968) 1.34
Coronary arterial relaxation and guanylate cyclase activation by cigarette smoke, N'-nitrosonornicotine and nitric oxide. J Pharmacol Exp Ther (1980) 1.31
Effects of several saluretic-diuretic agents on renal hemodynamics. J Pharmacol Exp Ther (1966) 1.27
Relaxation of intrapulmonary artery and vein by nitrogen oxide-containing vasodilators and cyclic GMP. J Pharmacol Exp Ther (1984) 1.23
Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther (1981) 1.22
Differences in responsiveness of intrapulmonary artery and vein to arachidonic acid: mechanism of arterial relaxation involves cyclic guanosine 3':5'-monophosphate and cyclic adenosine 3':5'-monophosphate. J Pharmacol Exp Ther (1985) 1.20
Attenuation of hydrochlorothiazide-induced hypokalemia in dogs by a beta-adrenergic blocking drug, timolol. Eur J Pharmacol (1975) 1.20
Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci U S A (1999) 1.16
A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol (2000) 1.16
Effect of chronic hypertension and sympathetic denervation on wall/lumen ratio of cerebral vessels. Hypertension (1980) 1.15
Neurohumoral mediation of active reflex vasodilatation. Fed Proc (1967) 1.14
Evidence for a neurotransmitter role for epinephrine derived from the adrenal medulla. Am J Physiol (1982) 1.11
L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun (1993) 1.11
The influence of cognitive bias on the perceived odor, irritation and health symptoms from chemical exposure. Int Arch Occup Environ Health (1997) 1.10
Histamine, norepinephrine and serotonin content of nasal polyps. Laryngoscope (1979) 1.07
Hemodynamic mechanisms of erection in the canine penis. Am J Physiol (1967) 1.07
Arterial pressure development in neonatal and young spontaneously hypertensive rats. Blood Vessels (1977) 1.03
Dissimilarities between methylene blue and cyanide on relaxation and cyclic GMP formation in endothelium-intact intrapulmonary artery caused by nitrogen oxide-containing vasodilators and acetylcholine. J Pharmacol Exp Ther (1986) 1.03
Perceived odor, irritation, and health symptoms following short-term exposure to acetone. Am J Ind Med (1997) 1.03
Prevention of the development of renal hypertension by anteroventral third ventricular tissue lesions. Circ Res (1977) 1.02
Influence of prostaglandins E1 and F2alpha on pulmonary vascular resistance, isolated lobar vessels and cyclic nucleotide levels. J Pharmacol Exp Ther (1975) 1.02
Pulmonary vasodilator activity of prostacyclin (PGI2) in the cat. Circ Res (1979) 1.02
Activation of vagal depressor reflexes by atriopeptins inhibits renal sympathetic nerve activity. Am J Physiol (1986) 1.01
Atriopeptin II relaxes and elevates cGMP in bovine pulmonary artery but not vein. J Appl Physiol (1985) (1986) 1.01
Evidence that regulation of hepatic guanylate cyclase activity involves interactions between catalytic site -SH groups and both substrate and activator. Arch Biochem Biophys (1981) 1.01
Distribution of vasodilator nerves in the canine hindlimb. Am J Physiol (1970) 1.01
Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2. J Appl Physiol Respir Environ Exerc Physiol (1978) 1.01
Renal vascular effects of endoperoxide analogs, prostaglandins, and arachidonic acid. Am J Physiol (1977) 1.00
Role of sympathetic nerve activity in the generation of vascular nitric oxide in urethane-anesthetized rats. Hypertension (1991) 0.98
Differential effects of ibuprofen and indomethacin in the regional circulation of the dog. J Pharmacol Exp Ther (1981) 0.98
Cardioprotection with sildenafil, a selective inhibitor of cyclic 3',5'-monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res (2002) 0.98
The pharmacological effects of allicin, a constituent of garlic oil. Agents Actions (1988) 0.97
Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res (1999) 0.97
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution. J Med Chem (1980) 0.97
Prostaglandins and the lung. Am Rev Respir Dis (1978) 0.96
Methylene blue selectively inhibits pulmonary vasodilator responses in cats. J Appl Physiol (1985) (1989) 0.95
Physiological and pharmacological roles of prostaglandins. Annu Rev Pharmacol (1975) 0.95
Circulatory effects of hydrocortisone and protection against endotoxin shock in cats. Eur J Pharmacol (1970) 0.95
Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (1995) 0.95
Differential effects of prostaglandins E 1 , E 2 , F 1 and F 2 on adrenergic vasoconstriction in the dog hindpaw. J Pharmacol Exp Ther (1971) 0.95
Effects of prostaglandins E1 and F2a on the swine pulmonary circulation. Proc Soc Exp Biol Med (1974) 0.95
Evidence for non-mast cell histamine in the vascular wall. Blood Vessels (1975) 0.94
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med (1996) 0.94
Neurogenic and humoral factors controlling vascular resistance in the spontaneously hypertensive rat. Circ Res (1974) 0.94
Bronchoactive metabolites of arachidonic acid and their role in airway function. Prostaglandins (1981) 0.93
Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol (1993) 0.93
A novel right-heart catheterization technique for in vivo measurement of vascular responses in lungs of intact mice. Am J Physiol Heart Circ Physiol (2000) 0.93
Differential effects of rat endothelin on regional blood flow in the cat. Eur J Pharmacol (1989) 0.93
Effects of porcine and rat endothelin and an analog on blood pressure in the anesthetized cat. Eur J Pharmacol (1989) 0.93
Influence of a prostaglandin endoperoxide analogue on the canine pulmonary vascular bed. Circ Res (1977) 0.93
Factors influencing the altered pain perception in the spontaneously hypertensive rat. Brain Res (1982) 0.92
N omega-nitro-L-arginine methyl ester selectively inhibits pulmonary vasodilator responses to acetylcholine and bradykinin. J Appl Physiol (1985) (1991) 0.92
Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease. Andrology (2014) 0.92
In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther (1992) 0.92
Vasopressin and vascular reactivity in the development of DOCA hypertension in rats with hereditary diabetes insipidus. Hypertension (1982) 0.91
Differential effects of prostaglandins in the mesenteric vascular bed. Am J Physiol (1978) 0.91
Cerebral vascular responses to physiological stimulation of sympathetic pathways in cats. Circ Res (1979) 0.91
Interruption of the maintenance phase of established hypertension by ablation of the anteroventral third ventricle (AV3V) in rats. Clin Exp Hypertens (1980) 0.90
Vasopressin-central nervous system interactions in the development of DOCA hypertension. Hypertension (1982) 0.90
Effect of prostaglandins E 1 , E 2 and A 2 on vascular resistance and responses to noradrenaline, nerve stimulation and angiotensin in the dog hindlimb. Br J Pharmacol (1972) 0.90
Oppositional effects of acetylcholine and isoproterenol on isometric tension and cyclic nucleotide concentrations in rabbit atria. J Cyclic Nucleotide Res (1975) 0.90
Influence of inhibitors of prostaglandin synthesis on venoconstrictor responses to bradykinin. J Pharmacol Exp Ther (1976) 0.90
Distribution of histamine in the canine autonomic nervous system. J Pharmacol Exp Ther (1970) 0.90
Actions of prostaglandins E1 and F2alpha on isolated intrapulmonary vascular smooth muscle. Proc Soc Exp Biol Med (1975) 0.90
Adenosine and ATP produce vasoconstriction in the feline pulmonary vascular bed by different mechanisms. J Pharmacol Exp Ther (1991) 0.90
Regulation of arterial pressure lability in rats with chronic sinoaortic deafferentation. Am J Physiol (1987) 0.89
Comparison of responses to novel nitric oxide donors in the feline pulmonary vascular bed. Eur J Pharmacol (2001) 0.89
Influence of prostaglandins E1 and F2a on pulmonary vascular resistance in the sheep. Proc Soc Exp Biol Med (1974) 0.89
N omega-nitro-L-arginine selectively inhibits vasodilator responses to acetylcholine and bradykinin in cats. Am J Physiol (1991) 0.89
Neural projections from paraventricular nucleus that subserve vasomotor functions. Am J Physiol (1985) 0.89
Vasoconstrictor hyperresponsiveness: an early pathogenic mechanism in the spontaneously hypertensive rat. Eur J Pharmacol (1978) 0.89
Evidence for existence of postjunctional alpha 1- and alpha 2-adrenoceptors in cat pulmonary vascular bed. Am J Physiol (1985) 0.89
Hemodynamic effects of vasodilator agents in dogs with experimental ventricular septal defects. Circulation (1976) 0.89
Pharmacotherapy for erectile dysfunction. Trends Pharmacol Sci (2000) 0.89
Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res (2004) 0.89
Acetone odor and irritation thresholds obtained from acetone-exposed factory workers and from control (occupationally unexposed) subjects. Am Ind Hyg Assoc J (1997) 0.89
Chronic lesion of rostral ventrolateral medulla in spontaneously hypertensive rats. Hypertension (1992) 0.89